Shares of Symbiotec Pharmalab rose over 8% after the US FDA issued an Establishment Inspection Report for its Pithampur facility, classifying the inspection as Voluntary Action Indicated. The company did not disclose details of the observations.
Shares of Symbiotec Pharmalab rose over 8% after the US FDA issued an Establishment Inspection Report for its Pithampur facility, classifying the inspection as Voluntary Action Indicated. The company did not disclose details of the observations.